{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:36:24Z","timestamp":1778801784137,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.leukres.2022.106951","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T07:15:54Z","timestamp":1662966954000},"page":"106951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation"],"prefix":"10.1016","volume":"121","author":[{"given":"Shin-ichiro","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Murahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotomo","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Toda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Umino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Minakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.leukres.2022.106951_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11864-017-0446-4","article-title":"What is the best daunorubicin dose and schedule for acute myeloid leukemia induction?","volume":"18","author":"Pophali","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2022.106951_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ejhf.654","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"19","author":"Zamorano","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.leukres.2022.106951_bib3","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"16","author":"Armenian","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2022.106951_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"issue":"32","key":"10.1016\/j.leukres.2022.106951_bib5","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2015.61.5187","article-title":"Equivalence ratio for daunorubicin to doxorubicin in relation to late heart failure in survivors of childhood cancer","volume":"33","author":"Feijen","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2022.106951_bib6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaoncol.2018.6634","article-title":"Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity","volume":"5","author":"Feijen","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.leukres.2022.106951_bib7","unstructured":"Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer. Survivorship Guidelines. version 5.0 October 2018 \u3008http:\/\/survivorshipguidelines.org\/\u3009."},{"issue":"3","key":"10.1016\/j.leukres.2022.106951_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11912-019-0774-6","article-title":"Cardiac complications in the adult bone marrow transplant patient","volume":"21","author":"Tuzovic","year":"2019","journal-title":"Curr. Oncol. Rep."},{"issue":"11","key":"10.1016\/j.leukres.2022.106951_bib9","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/s41409-021-01427-2","article-title":"Cardiac complications associated with hematopoietic stem-cell transplantation","volume":"56","author":"Ohmoto","year":"2021","journal-title":"Bone Marrow Transpl."},{"issue":"8","key":"10.1016\/j.leukres.2022.106951_bib10","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","article-title":"Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201","volume":"117","author":"Ohtake","year":"2011","journal-title":"Study Blood"},{"issue":"8","key":"10.1016\/j.leukres.2022.106951_bib11","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2010-07-295279","article-title":"A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201","volume":"117","author":"Miyawaki","year":"2011","journal-title":"Study Blood"},{"issue":"11","key":"10.1016\/j.leukres.2022.106951_bib12","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3109\/10428194.2016.1153087","article-title":"Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia","volume":"57","author":"Yamamoto","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2022.106951_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.leukres.2015.12.013","article-title":"A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: a propensity score analysis","volume":"42","author":"Minakata","year":"2016","journal-title":"Leuk. Res."},{"issue":"10","key":"10.1016\/j.leukres.2022.106951_bib14","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/0959-8049(92)90066-B","article-title":"Early assessment of a new anticancer drug analogue--are the historical comparisons obsolete? The French experience with pirarubicin","volume":"28a","author":"Herait","year":"1992","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2022.106951_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0277-5379(83)90140-2","article-title":"Antitumor activity in mice of 4\u2032-deoxydoxorubicin in comparison with doxorubicin","volume":"19","author":"Casazza","year":"1983","journal-title":"Eur. J. Cancer Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2022.106951_bib16","first-page":"685","article-title":"Antitumor activity of new anthracycline antibiotics, aclacinomycin-A and its analogs, and their toxicity","volume":"68","author":"Hori","year":"1977","journal-title":"Gan"},{"issue":"3","key":"10.1016\/j.leukres.2022.106951_bib17","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"issue":"8","key":"10.1016\/j.leukres.2022.106951_bib18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.leukres.2022.106951_bib19","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/bloodadvances.2018019117","article-title":"Prediction of cardiovascular disease among hematopoietic cell transplantation survivors","volume":"2","author":"Armenian","year":"2018","journal-title":"Blood Adv."},{"issue":"25","key":"10.1016\/j.leukres.2022.106951_bib20","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2022.106951_bib21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12185-022-03343-7","article-title":"Comparison of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"116","author":"Hayakawa","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2022.106951_bib22","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Acute Myeloid Leukemia Version 1.2022 \u3008https:\/\/www.nccn.org\/guidelines\/category_1pp\u3009."},{"issue":"5","key":"10.1016\/j.leukres.2022.106951_bib23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12185-020-02856-3","article-title":"JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML)","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Int. J. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2022.106951_bib24","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.31557\/APJCP.2021.22.5.1407","article-title":"Risk factors of daunorubicine induced early cardiotoxicity in childhood acute lymphoblastic leukemia: a retrospective study","volume":"22","author":"Samosir","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"4","key":"10.1016\/j.leukres.2022.106951_bib25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/bloodadvances.2019000955","article-title":"Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper","volume":"4","author":"Neuendorff","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.leukres.2022.106951_bib26","first-page":"213","article-title":"[Assessment of anthracycline cardiotoxicity by radionuclide angiocardiography]","volume":"28","author":"Morikawa","year":"1987","journal-title":"Rinsho Ketsueki"},{"issue":"1","key":"10.1016\/j.leukres.2022.106951_bib27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13293-018-0198-2","article-title":"Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity","volume":"9","author":"Meiners","year":"2018","journal-title":"Biol. Sex Differ."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:34Z","timestamp":1758935014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622001771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":27,"alternative-id":["S0145212622001771"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106951","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106951"}}